scholarly journals Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter, 225Ac, and beta-particle emitter, 177Lu

Author(s):  
Vladimir Shalgunov ◽  
Gokce Engudar ◽  
Lennart Bohrmann ◽  
Luke Wharton ◽  
Keiran Maskell ◽  
...  

It is well known that the absorption of neutrons in their passage through matter is due to nuclear collisions, and not appreciably to interaction with extranuclear electrons. A collision of a neutron with a nucleus may result in the scattering of the neutron, or in the disintegration of the nucleus. The experiments of Feather and of Harkins, Gans, and Newson§ have shown that several light elements, C, N, O, F, Ne are disintegrated, the mechanism probably being absorption of the neutron and emission of an alpha particle. Fermi|| has reported that a variety of elements when bombarded by neutrons show the phenomenon of induced radioactivity, emitting beta rays. He suggests that the disintegration process takes place usually by absorption of a neutron and emission of an alpha particle or proton, the resulting nucleus being an unstable radio element, transforming into a stable body by emission of a beta particle. The experiments here to be described show that when neutrons pass through various substances, gamma rays are produced. The origin of this radiation has not definitely been established; nuclear excitation appears to be the most plausible explanation in most cases. 2—Experimental Method The general method consisted in measuring the ionization current produced by a Po + Be source (usually of about 10-15 millicuries) placed above a high pressure ionization chamber, and observing the increased ionization when a block of scattering material was placed immediately above the source. A correction was applied for the diminution of the natural effect caused by the scatterer. The increase in ionization amounted usually to 2-3%, and thus to obtain even a rough measurement of the effect, accurate measurements of the ionization currents were required. For this reason the high pressure ionization chamber was usually used in preference to the counter, since measurements to one part in a thousand are impracticable with the latter. The ionization method has, however, the disadvantage that both gamma rays and neutrons are detected. To distinguish between the two radiations, two similar ionization chambers were used, one containing argon at a pressure of 90 atmospheres, the other hydrogen at about 60 atmospheres. The former is more sensitive to gamma radiation, the latter to neutrons. The ionization chambers were of steel and had cylindrical walls 1 cm thick; the radiations entered through the roofs of the chambers, which were 2·5 cm thick. The inside dimensions were 16 cm high and 12 cm diameter, with a 2-cm diameter central electrode. Collecting potentials of 250-500 volts were used. Measurements were made by a balance method and followed standard practice. From the measurements of ionization currents in argon and hydrogen estimates may be made of the neutron ( n ) and gamma ray (γ) intensities separately. The method by which this is achieved is described in § 11.


2018 ◽  
Vol 108 (3) ◽  
pp. 256-264 ◽  
Author(s):  
Shaunak Navalkissoor ◽  
Ashley Grossman

Neuroendocrine tumours (NETs) are being seen increasingly frequently, but to date only complete surgical resection is curative. However, among the various therapeutic options, peptide receptor radionuclide therapy, linking a radioactive moiety to an octreotide derivative, has been shown to be highly efficacious and a well-tolerated therapy, improving progression-free survival and probably overall survival. Nevertheless, the current radionuclides in use are beta particle emitters with non-optimal radiobiological properties. A new generation of alpha particle-emitting radionuclides is being developed, with advantages in terms of very high energy and a short path length, which should theoretically show higher efficacy. We survey the current developments in this field, emphasising the exciting potential of this novel form of therapy for NETs.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4415-4415
Author(s):  
Damian J. Green ◽  
Mazyar Shadman ◽  
Shani L. Frayo ◽  
Jon C. Jones ◽  
Mark D. Hylarides ◽  
...  

Stem cell rescue after myeloablative doses of beta particle emitting radiolabeled monoclonal antibodies targeting CD20 antigen can lead to remissions in up to 95% of lymphoma patients who previously failed conventional combination chemotherapy. While encouraging, toxicities with beta particle radioimmunotherapy (RIT) are significant and ∼50% of patients ultimately relapse. Higher doses of absorbed radiation to tumors have correlated with a reduced risk of disease recurrence but dose limiting toxicities prevent escalation. A potential advantage of alpha particle emitting radionuclides is the release of large amounts of energy linearly over a few cell diameters (∼50-80 mm) resulting in irreparable double-strand DNA breaks that overwhelm cellular repair mechanisms. As a result, alpha particles confer a unique capacity to kill individual targeted cells while causing minimal radiation damage to surrounding tissues. To explore alpha-emitter conjugated anti-CD20 RIT, a closo-decaborate(2-) [B10] labeling reagent was developed as a radiolabeling platform capable of providing critical stability to alpha particle-labeled biomolecules. 211At was chosen as a therapeutic radionuclide based on its high linear energy transfer, biologically relevant t1/2 (∼7.2 hr) and absence of toxic daughter radionuclide decay byproducts. Cell binding assays using CD20-expressing Ramos tumor cells demonstrated that B10 conjugated to the anti-CD20 monoclonal antibody (mAb) 1F5 (B10-1F5) was specific and that astatination did not impair antibody binding (211At-B10-1F5 binding was equivalent to 125I-B10-1F5). Blood clearance was similar for 125I-1F5, 211At-B10-1F5 and 125I-B10-1F5 in athymic nude- Foxn1nu mice (23.87 ±5.13 % injected dose/gram [ID/g], 19.41 ±3.27 %ID/g and 19.80 ±1.44% ID/g respectively) at 17 hr post infusion. In tissue biodistribution studies using nude mice bearing Ramos flank tumor xenografts (10 x106 cells injected) radioactivity was measured in blood, tumor and nonspecific organs harvested 24 hours after injection (n=5/group). Animals received either 125I-1F5, 211At-B10-1F5 and 125I-B10-1F5 (co-injected) or isotype matched control mAb 211At- B10-HB8181 and125I-B10-HB8181(co-injected). Measured activity in tumors was three-fold higher for 125I-1F5, 125I-B10-1F5 and 211At-B10-1F5 (7.62 ± 2.09%ID/g, 7.53 ± 1.59%ID/g and 9.28 ± 1.85%ID/g respectively) than for 125I-B10-HB8181 and 211At-B10-HB8181 controls (2.87 ± 0.35%ID/g and 3.45 ± 0.58%ID/g respectively). In non-target organs no appreciable difference in measured activity was seen with either 211At- or 125I-labeled B10-1F5 and their respective controls. Subsequent therapy studies performed in nude mice bearing Ramos flank tumor xenografts demonstrated only a moderate survival advantage after 211At-B10-1F5 [data not shown]. This finding was consistent with the hypothesis that the alpha particle's short path length may not be ideally suited to models of “bulky” disease. In contrast, therapy studies using disseminated Ramos and Granta tumor cells introduced into NOD-SCID mice suggest a role for alpha particle based RIT in “non-bulky” disease models. In these studies NOD-SCID animals received 1x106 tumor cells iv 48 hours prior to 211At-B10-1F5 (10 μCi or 15 μCi) or control 211At-B10-HB8181 (n=10/group). Stem cell rescue was performed 48 hours after the RIT. Eighty days after treatment 80% of animals receiving 15 μCi of 211At-B10-1F5 and 70% of animals in the 10 μCi treatment group were alive and tumor free while no animals in the non-binding 211At-B10-HB8181 (10 μCi or 15 μCi) control groups survived beyond day 47 (Figure). Blood counts, serum creatinine and transaminase levels measured in 211At-B10-1F5 treated animals ∼180 days after RIT demonstrated no significant long-term bone marrow, renal or liver toxicity. 211At-B10-1F5 can eliminate CD20 expressing tumor cells in this mouse model and further study appears to be warranted. Disclosures: No relevant conflicts of interest to declare.


1971 ◽  
Vol 32 (C6) ◽  
pp. C6-185-C6-187
Author(s):  
A. DUDEK ◽  
P. E. HODGSON

Sign in / Sign up

Export Citation Format

Share Document